Skip to content
DataLookout
Menu

NCT03729180

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 7 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Aug 22, 2027 to Aug 22, 2028 Show 4 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site contact updated
    • Publications: details revised at 3 of 3 entries
  2. Minor Collaborators expanded, about 6 wordsv10
  3. Notable Primary and study completion dates: Aug 22, 2025 to Aug 22, 2027v9
  4. Notable Primary completion date: Aug 22, 2023 to Aug 22, 2025v7
  5. Minor Study title expanded, about 3 wordsv3
  6. Notable Phase: Not specified to Not applicablev2 Show 8 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 1000 to 1900
    • Primary completion date: Oct 7, 2022 to Aug 22, 2023
    • Study sites: 0 to 1
    • Study completion date: Oct 7, 2024 to Aug 22, 2025
    • Start date changed from estimate of Oct 7, 2019 to Jan 22, 2019
    • Interventions: Blood test for genetic testing (Diagnostic Test), Drug-genetic Profile (Other), Routine Elective Surgery (Procedure) to Blood test for genetic testing (Diagnostic Test), Drug-genetic Profile (Other), Routine Elective Surgery- In patient or out patient…
    • Secondary endpoints: details revised at 6 of 6 entries
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.
Timeframe: 5 years
Rate of use of high-risk drugs in perioperative setting
Timeframe: 5 years

Secondary (6)

Rate of use of favorable drugs in perioperative setting
Occurrence of specific pharmacogenomically-informed adverse drug events
Pharmacogenomic result availability on pain management services in both arms using a research database for each patient
Comparison of pain scores on a 10 point scale
Anesthesia and critical care providers knowledge and perceptions of prescribing decisions using a information provided in research database
Show 1 moreShow less
Differences in patient reported satisfaction using research database

Arms and interventions

Pain CohortOther

Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.

Pharmacogenomic (PGx) Arm [Randomization Arm 1]Experimental

All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.

Control Arm [Randomization Arm 2]Other

All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.

Procedures: Routine Elective Surgery- In patient or out patient elective surgery

Diagnostic tests: Blood test for genetic testing

Other: Drug-genetic Profile

Sites

1 site in 1 country

  • University Of Chicago Medicine Comprehensive Cancer CenterChicago, Illinois, United States